Eli Lilly and Co - Company Profile
Powered by
All the data and insights you need on Eli Lilly and Co in one report.
- Save hours of research time and resources with
our up-to-date Eli Lilly and Co Strategy Report
- Understand Eli Lilly and Co position in the market,
performance and strategic initiatives.
- Gain competitive edge and increase your
chances of success
Eli Lilly and Co (Lilly) is a healthcare company that discovers, develops, and markets human healthcare products. The company offers medicines for cardiovascular conditions, diabetes, endocrinology, cancer, neurological problems, autoimmune disorders, men's health, and musculoskeletal problems. The company distributes its pharmaceutical health products through independent wholesale distributors. Lilly conducts research and development activities to discover and deliver innovative medicines. It promotes products through sales representatives and marketing agreements with other pharmaceutical companies. The company operates R&D facilities, and production and distribution facilities in North America, South America, Europe, the Middle East, Africa and Asia-Pacific. Lilly is headquartered in Indianapolis, Indiana, the US.
Eli Lilly and Co premium industry data and analytics
Products and Services
Products | Brands |
---|---|
Human Pharmaceutical | - |
Endocrinology Products | Humalog |
Neuroscience Products | Humulin |
XYZ | XYZ |
XYZ | XYZ |
XYZ | XYZ |
History
History section provides information on new products, mergers, acquisitions, expansions, approvals, and many more key events.
Year | Event | Description |
---|---|---|
2024 | Contracts/Agreements | In April, the company signed an agreement to acquire a sterile manufacturing facility from Nexus Pharmaceuticals. |
2024 | Contracts/Agreements | In March, Eli Lilly Japan K.K entered into an alliance agreement with Nippon Shinyaku to deliver pirtobrutinib. |
2024 | Plans/Strategy | In March, the company announced its plans to launch Mounjaro, a diabetes and weight loss drug, in India. |
Competitor Comparison
Key Parameters | Eli Lilly and Co | Johnson & Johnson | F. Hoffmann-La Roche Ltd | Merck & Co Inc | Pfizer Inc |
---|---|---|---|---|---|
Headquarters | United States of America | United States of America | Switzerland | United States of America | United States of America |
City | Indianapolis | New Brunswick | Basel | Kenilworth | New York |
State/Province | Indiana | New Jersey | - | New Jersey | New York |
No. of Employees | 43,000 | 131,900 | 103,605 | 72,000 | 88,000 |
Entity Type | Public | Public | Public | Public | Public |
Key Financial Charts
Sales Growth
Net Income Growth
Executives
Name | Position | Board | Since | Age |
---|---|---|---|---|
David A. Ricks | Chairman; Chief Executive Officer; President | Executive Board | 2017 | 56 |
Anat Ashkenazi | Executive Vice President; Chief Financial Officer | Senior Management | 2021 | 51 |
Daniel M. Skovronsky, M.D., Ph.D. | Chief Scientific Officer; President - Lilly Research Laboratories and Immunology; Executive Vice President | Senior Management | 2024 | 50 |
Alonzo Weems | Chief Ethics and Compliance Officer; Executive Vice President - Enterprise Risk Management | Senior Management | 2021 | 53 |
Diogo Rau | Chief Information and Digital Officer; Executive Vice President | Senior Management | 2021 | 49 |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Non Dignissim Eros | Proin vel | Convallis | 2024 | XY |
Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.
Access more premium companies when you subscribe to Explorer
Get in touch about GlobalData Company reports
Contact the team or request a demo to find out how our data can drive your business forward